VectivBio Holding AG (VECT)
|Phone||41 61 551 30 3|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
VectivBio Holding is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need.
Our goal is to become a leading, patient-centric, fully integrated global rare disease company. Our current product pipeline is focused on rare gastrointestinal, or GI, disorders, and we intend to in-license or acquire additional transformational, differentiated rare disease assets.
Our product candidate, apraglutide, is a next generation, long-acting synthetic peptide analog of glucagon-like peptide-2, or GLP-2, which we are developing as a differentiated therapeutic for a range of rare GI diseases, with an initial focus on short bowel syndrome, or SBS.
Apraglutide is currently being evaluated in a global Phase 3 clinical trial for the treatment of patients with SBS intestinal failure, or SBS-IF. We also plan to evaluate apraglutide’s therapeutic potential in additional rare GI conditions, such as graft versus host disease, that could benefit from GLP-2 activation.
|Dr. Luca Santarelli M.D.||Founder, Chief Executive Officer and Director|
|Claudia D'Augusta Ph.D.||Chief Financial Officer|
|Dr. Christian Meyer||Chief Operating Officer|
|Dr. Alain Bernard Ph.D.||Chief Technology Officer|
|Kevin Harris||Chief Commercial Officer|
|Dr. Sarah Holland Ph.D.||Chief Business Officer|
|Dr. Omar Khwaja M.D., Ph.D.||Chief Medical Officer|
Latest SEC Filings
|Jul 12, 2021||6-K||Report of foreign issuer [Rules 13a-16 and 15d-16]|
|Apr 26, 2021||S-8||Securities to be offered to employees in employee benefit plans|
|Apr 23, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Apr 23, 2021||SC 13D||General statement of acquisition of beneficial ownership|
|Apr 20, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Apr 19, 2021||SC 13D||General statement of acquisition of beneficial ownership|
|Apr 14, 2021||SC 13G||Statement of acquisition of beneficial ownership by individuals|
|Apr 9, 2021||424B4||Prospectus [Rule 424(b)(4)]|
|Apr 9, 2021||EFFECT||Notice of Effectiveness|
|Apr 8, 2021||CERT||Certification by an exchange approving securities for listing|
|View All SEC filings|